+878.9%
WULF vs MRNA
+34.8%
+844.1%
-74.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.7% | +5.4% | -1.7% | +3.3% |
| 7D | +1.4% | -1.1% | +2.5% | +1.4% |
| 30D | -2.6% | +126.1% | -128.7% | -14.5% |
| 3M | -34.0% | +190.0% | -224.0% | -47.0% |
| 6M | +10.0% | +157.2% | -147.2% | -9.1% |
| YTD | +45.7% | +388.2% | -342.5% | -2.4% |
| 1Y | +57.3% | +467.0% | -409.7% | -1.7% |
| 3Y | +878.9% | +36.1% | +842.9% | +660.2% |
| All | +878.9% | +34.8% | +844.1% | +660.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling